| Literature DB >> 30213053 |
Bastián Said1, Iván Montenegro2, Manuel Valenzuela3, Yusser Olguín4, Nelson Caro5, Enrique Werner6, Patricio Godoy7, Joan Villena8, Alejandro Madrid9.
Abstract
Six new cyclodiprenyl phenols were synthesized by direct coupling of perillyl alcohol and the appropriate phenol. Their structures were established by IR, HRMS and mainly NMR. Three human cancer cell lines-breast (MCF-7), prostate (PC-3) and colon (HT-29)-were used in antiproliferative assays, with daunorubicin and dunnione as positive controls. Results described in the article suggest that dihydroxylated compounds 2⁻4 and monohydroxylated compound 5 display selectivity against cancer cell lines, cytotoxicity, apoptosis induction, and mitochondrial membrane impairment capacity. Compound 2 was identified as the most effective of the series by displaying against all cancer cell lines a cytotoxicity close to dunnione antineoplastic agent, suggesting that the cyclodiprenyl phenols from perillyl alcohol deserve more extensive investigation of their potential medicinal applications.Entities:
Keywords: antiproliferative agents; cyclodiprenyl phenols; perillyl alcohol; synthesis
Mesh:
Substances:
Year: 2018 PMID: 30213053 PMCID: PMC6225466 DOI: 10.3390/molecules23092323
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of cyclodiprenyl phenols 2–7. Reagents and conditions: (i) BF3·OEt2, CH3CN, N2 at r.t. for 48 h.; (A) pyrocatechol; (B) resorcinol; (C) hydroquinone; (D) pyrogallol; (E) phloroglucinol.
Figure 1Most important correlations 2D 1H–13C HMBC of compounds 2–5.
Figure 2Most important correlations 2D 1H–13C HMBC of compounds 6 and 7.
In vitro cytotoxic activity of natural compound 1 and derivatives 2–7.
| Compound | IC50 (µM) | ||||
|---|---|---|---|---|---|
| MCF-7 | PC-3 | HT-29 | CoN | HDF | |
|
| >100 | >100 | >100 | >100 | >100 |
|
| 25.9 ± 0.1 | 12.2 ± 0.7 | 45.1 ± 0.2 | >100 | >100 |
|
| 53.7 ± 0.4 | 54.5 ± 0.5 | >100 | >100 | >100 |
|
| 44.3 ± 0.7 | 79.0 ± 0.2 | >100 | >100 | >100 |
|
| 37.0 ± 0.1 | 20.5 ± 0.4 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 | >100 |
| Dunnione | 14.56 ± 0.04 | 26.51 ± 0.05 | 30.32 ± 0.05 | 24.07 ± 0.55 | 27.03 ± 0.65 |
| Daunorubicin | 0.21 ± 0.01 | 0.39 ± 0.06 | 14.7 ± 0.9 | - | 14.09 ± 0.45 |
Percentage of condensed and/or fragmented nuclei after treatment with compounds 2–5.
| Compound | MCF-7 | PC-3 | HDF |
|---|---|---|---|
|
| 29.4 ± 4.3 ** | 31.4 ± 3.3 ** | 8.7 ± 1.4 |
|
| 16.8 ± 3.1 * | 14.5 ± 3.1 * | 6.8 ± 1.6 |
|
| 17.2 ± 2.9 * | 13.8 ± 2.1 * | 5.6 ± 1.1 |
|
| 7.3 ± 1.4 | 6.0 ± 0.3 | 7.9 ± 1.2 |
| Control | 6.7 ± 1.5 | 8.6 ± 1.0 | 6.0 ± 1.1 |
Values are mean ± S.D. (n = 3); * p < 0.05; ** p < 0.01, significantly different from the control-treated cells.
Percentage of cells without rhodamine-123 after treatment with compounds 2–4 on MCF-7 and PC-3-treated cells.
| Compound | MCF-7 | PC-3 |
|---|---|---|
|
| 69.4 ± 4.3 ** | 41.4 ± 4.8 * |
|
| 28.9 ± 2.4 * | 29.5 ± 3.7 * |
|
| 34.2 ± 4.9 * | 26.5 ± 3.8 * |
| Control | 23.0 ± 2.1 | 15.6 ± 4.0 |
Values are mean ± S.D. (n = 3); * p < 0.05; ** p < 0.01, significantly different from the control-treated cells.
Figure 3Effect of treatment with compounds 2–4 in mitochondrial membrane permeability in MCF-7 cell line was analyzed by flow cytometry. Cells were treated with compounds (25 µM), posteriorly stained with rhodamine 123 and then analyzed by flow cytometry. Representative histogram showing changes of mitochondrial membrane permeability.
Percentage of cells with caspases active on MCF-7 and PC-3-treated cells.
| Compound | MCF-7 | PC-3 |
|---|---|---|
|
| 32.4 ± 4.0 ** | 23.4 ± 3.0 * |
|
| 15.1 ± 3.2 * | 16.5 ± 2.3 * |
|
| 21.4 ± 2.9 * | 19.1 ± 2.8 * |
| Control | 9.1 ± 2.1 | 8.9 ± 2.1 |
Values are mean ± S.D. (n = 3); * p < 0.05; ** p < 0.01, significantly different from the control-treated cells.
Figure 4Effect of compounds 2–4 on caspases activity in PC-3 cell line was analyzed by flow cytometry. Cells were treated with compounds (25 µM), posteriorly stained with CaspACE™ FITC-VAD-FMK and then analyzed by flow cytometry. Representative histogram showing changes on caspases activity.